RNA, U4 small nuclear 16, pseudogeneGenealiases: []
Q-omics provides the consensus-scored RNU4-16P profile across patient tissues and cancer cell-line models. RNU4-16P expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNU4-16P is differentially expressed in 1, with the highest sampling consensus in KIRP. Additionally, RNU4-16P RNA expression shows 8,868 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KIRP, and GBM as cancer lineages where RNU4-16P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNU4-16P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNU4-16P survival associations across molecular data types. RNU4-16P RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNU4-16P RNA expression–survival associations across cancer types. High RNU4-16P expression shows unfavorable associations in KIRC, PAAD, THCA, CHOL and COAD, but favorable associations in BLCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNU4-16P RNA expression.
This table summarizes RNU4-16P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for RNU4-16P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNU4-16P shows higher tumor expression in KIRP. The KIRP box plot shows higher RNU4-16P RNA expression in tumor versus normal tissue (log2 FC = +0.070, t-test p = .033).
This table shows molecular features associated with RNU4-16P in patient tissues and cancer cell lines. In patient samples, RNU4-16P shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
